Poliovirus Vaccines: Bivalent vs. Trivalent

After one and two doses, seroconversion rates were higher with bivalent vaccine than with trivalent vaccine.

Despite progress in efforts to eradicate poliomyelitis, polioviruses types 1 and 3 continue to cocirculate in the four remaining endemic countries (India, Pakistan, Afghanistan, and Nigeria). Could use of a bivalent oral poliovirus vaccine (bOPV) with types 1 and 3 produce higher levels of seroconversion than trivalent vaccines, in which type 2 virus can interfere with immune responses to types 1 and 3?

To find out, investigators (with partial industry support) conducted a double-blind, multicenter trial. Nine hundred healthy newborn infants in India were randomized to receive one of five formulations of oral poliovirus vaccine: monovalent type 1 OPV (mOPV1), mOPV2, mOPV3, trivalent OPV (tOPV), or bOPV containing types 1 and 3 poliovirus. On…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine